Today in press releases: The U.S. Food and Drug Administration (FDA) has granted approval for LIALDA™ (mesalamine) with MMX® technology for the induction of remission in patients with active, mild to moderate ulcerative colitis.

If you do not know much about the disease, here is the information:

Ulcerative colitis is a type of inflammatory bowel disease (IBD) that produces inflammation and sores or ulcers along the inside of the large intestine, also called the bowel or colon. The sores can interfere with the normal digestive process, often causing cramping, bloating, diarrhea, bleeding, fatigue, weight loss and frequent bowel movements.

Mesalamine and other NSAIDs were often considered as one of the main therapies for autoimmune disorders.

Once daily is easier to remember and to stick to in your daily routine.